These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36355761)

  • 41. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
    Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
    J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy.
    Mikolasevic I; Domislovic V; Krznaric-Zrnic I; Krznaric Z; Virovic-Jukic L; Stojsavljevic S; Grgurevic I; Milic S; Vukoja I; Puz P; Aralica M; Hauser G
    Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208576
    [No Abstract]   [Full Text] [Related]  

  • 43. Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis?
    Türker F; Oral A; Şahin T; Türker BÇ; Koçak E; Ataoğlu HE; Ahbab S
    J Int Med Res; 2021 Nov; 49(11):3000605211056841. PubMed ID: 34763561
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early detection of liver fibrosis with serum Mac-2 binding protein glycosylation-modified isomer (M2BPGi) during follow-up intestinal failure patients without intestinal failure-associated liver disease (IFALD).
    Ueno T; Takase K; Deguchi K; Masahata K; Nomura M; Watanabe M; Kamiyama M; Tazuke Y; Bessho K; Okuyama H
    Pediatr Surg Int; 2022 Dec; 38(12):1807-1813. PubMed ID: 36125546
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C.
    Xu H; Kong W; Liu L; Chi X; Wang X; Wu R; Gao X; Wang H; Qu L; Qi Y; Pan Y; Niu J
    BMC Gastroenterol; 2017 May; 17(1):62. PubMed ID: 28486931
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study.
    Tan EX; Lee JW; Jumat NH; Chan WK; Treeprasertsuk S; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Lesmana LA; Zheng KI; Zheng MH; Koh CJ; Ho KY; Goh KL; Wong VW; Dan YY
    Metabolism; 2022 Jan; 126():154911. PubMed ID: 34648769
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of Non-Invasive Clinical Algorithms for Liver Fibrosis in Patients With Chronic Hepatitis B to Reduce the Need for Liver Biopsy: Application of Enhanced Liver Fibrosis and Mac-2 Binding Protein Glycosylation Isomer.
    Hur M; Park M; Moon HW; Choe WH; Lee CH
    Ann Lab Med; 2022 Mar; 42(2):249-257. PubMed ID: 34635616
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum Mac-2 binding protein glycosylation isomer as a biomarker of fibrosis in living donor liver transplant graft.
    Sasaki R; Miyaaki H; Narita S; Fukushima M; Haraguchi M; Miuma S; Hidaka M; Eguchi S; Okudaira S; Abe K; Nakao K
    Clin Transplant; 2021 Feb; 35(2):e14175. PubMed ID: 33247961
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria.
    Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Jang JY; Park SY; Lee HW; Lee CK; Kim SU
    Front Med (Lausanne); 2022; 9():869190. PubMed ID: 35492369
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
    Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
    JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients.
    Jang TY; Huang CF; Yeh ML; Huang CI; Dai CY; Tsai PC; Hsu PY; Wei YJ; Hou NJ; Liang PC; Lin YH; Wang CW; Hsieh MY; Lin ZY; Huang JF; Yu ML; Chuang WL
    Kaohsiung J Med Sci; 2022 Mar; 38(3):261-267. PubMed ID: 34786828
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
    Papatheodoridi M; Cholongitas E
    Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
    Kanno M; Kawaguchi K; Honda M; Horii R; Takatori H; Shimakami T; Kitamura K; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
    J Gastroenterol; 2019 Jun; 54(6):549-557. PubMed ID: 30707282
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.
    Chuah KH; Wan Yusoff WNI; Sthaneshwar P; Nik Mustapha NR; Mahadeva S; Chan WK
    Liver Int; 2019 Jul; 39(7):1315-1324. PubMed ID: 30825254
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging.
    Santiago-Rolón A; Purcell D; Rosado K; Toro DH
    P R Health Sci J; 2015 Dec; 34(4):189-94. PubMed ID: 26602577
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Histological Evaluation of Non-alcoholic Fatty Liver Disease and Its Correlation with Different Noninvasive Scoring Systems with Special Reference to Fibrosis: A Single Center Experience.
    Rath MM; Panigrahi MK; Pattnaik K; Bhuyan P; Kar SK; Misra B; Misra D; Meher C; Agrawal O; Rath J; Singh SP
    J Clin Exp Hepatol; 2016 Dec; 6(4):291-296. PubMed ID: 28003718
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
    Arora A; Sharma P
    J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.